Prana appoints US analyst to board

By Melissa Trudinger
Thursday, 25 March, 2004

Melbourne biotech company Prana Biotechnology (ASX: PBT) has appointed leading US biotech analyst Dr Jonas Alsenas to its board of directors.

Most recently, Alsenas managed a hedge fund with an emphasis on biotechnology for ING Investment Management, New York.

"[Alsenas] is held in high regard in the international biotech sector and possesses an extensive knowledge of the industry in which Prana operates. Hi understanding of, and fundamental belief in, our technology and business strategy will help to shape Prana's future," said Prana CEO Geoffrey Kempler.

Related News

Frequent nightmares accelerate aging, increase risk of death

Nghtmares independently predict faster biological aging and earlier mortality — even after...

Cardiac organoids bring hope for treating heart disease

Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...

Indigenous-led initiative to resurrect the South Island Giant Moa

New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd